EP2484670A4 - SUBSTITUTED 1,2,4-TIADIAZOLES-5-IMINO USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - Google Patents

SUBSTITUTED 1,2,4-TIADIAZOLES-5-IMINO USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

Info

Publication number: EP2484670A4
Authority: EP; European Patent Office
Prior art keywords: tiadiazoles; imino; substituted; useful; treatment
Prior art date: 2009-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP10819948A

Other languages

German (de)

French (fr)

Other versions

EP2484670B1 (en

EP2484670A1 (en

Inventor

Gil Ana Martinez

Ayuso-Gontan Carmen Gil

Ruiz Valle Palomo

Fernandez Daniel Perez

Martin Concepcion Perez

Castillo Ana Maria Perez

Garcia Maria Isabel Loza

Torres Maria Isabel Cadavid

Floriani Jose Brea

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Consejo Superior de Investigaciones Cientificas CSIC

Original Assignee

Consejo Superior de Investigaciones Cientificas CSIC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-02

Filing date

2010-10-04

Publication date

2013-03-13

2010-10-04 Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC

2012-08-08 Publication of EP2484670A1 publication Critical patent/EP2484670A1/en

2013-03-13 Publication of EP2484670A4 publication Critical patent/EP2484670A4/en

2016-07-20 Application granted granted Critical

2016-07-20 Publication of EP2484670B1 publication Critical patent/EP2484670B1/en

Status Active legal-status Critical Current

2030-10-04 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP10819948.0A 2009-10-02 2010-10-04 Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases Active EP2484670B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200930787A ES2360783B1 (en)	2009-10-02	2009-10-02	1,2,4-TIADIAZOLES-5-IMINO USEFUL SUBSTITUTES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
PCT/ES2010/070641 WO2011039403A1 (en)	2009-10-02	2010-10-04	Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases

Publications (3)

Publication Number	Publication Date
EP2484670A1 EP2484670A1 (en)	2012-08-08
EP2484670A4 true EP2484670A4 (en)	2013-03-13
EP2484670B1 EP2484670B1 (en)	2016-07-20

Family

ID=43825604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP10819948.0A Active EP2484670B1 (en)	2009-10-02	2010-10-04	Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases

Country Status (7)

Country	Link
US (1)	US9604947B2 (en)
EP (1)	EP2484670B1 (en)
AU (1)	AU2010302536B2 (en)
CA (1)	CA2780695C (en)
DK (1)	DK2484670T3 (en)
ES (1)	ES2360783B1 (en)
WO (1)	WO2011039403A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014031732A2 (en) *	2012-08-22	2014-02-27	Cornell University	Methods for inhibiting fascin
CN106232583B (en)	2014-02-20	2020-04-24	康奈尔大学	Compounds and methods for inhibiting fascin
CN104502522A (en) *	2015-01-07	2015-04-08	杭州哲博化工科技有限公司	Galactose nitryl phenylhydrazone, preparation method of galactose nitryl phenylhydrazone, as well as application of galactose nitryl phenylhydrazone to detection of fluorinion
WO2016172496A1 (en)	2015-04-23	2016-10-27	Constellation Pharmaceuticals, Inc.	Lsd1 inhibitors and uses thereof
ES2961499T3 (en)	2016-10-26	2024-03-12	Constellation Pharmaceuticals Inc	LSD1 inhibitors and their medical uses
EP3827665B1 (en)	2019-11-26	2025-02-19	Consejo Superior de Investigaciones Científicas (CSIC)	Mammal kinase inhibitors to promote in vitro embryogenesis induction of plants
CN119768172A (en)	2022-08-18	2025-04-04	米托迪治愈有限责任公司	Use of therapeutic agents having phosphodiesterase-7 inhibitory activity in the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertion intolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ532883A (en) *	2001-11-08	2007-09-28	Ortho Mcneil Pharm Inc	Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7319107B2 (en) *	2001-11-08	2008-01-15	Johnson & Johnson Consumer Companies, Inc.	1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
CN101917992A (en)	2007-03-27	2010-12-15	奥默罗斯公司	Use of PDE7 inhibitors for the treatment of movement disorders

2009
- 2009-10-02 ES ES200930787A patent/ES2360783B1/en not_active Expired - Fee Related
2010
- 2010-10-04 CA CA2780695A patent/CA2780695C/en active Active
- 2010-10-04 WO PCT/ES2010/070641 patent/WO2011039403A1/en not_active Ceased
- 2010-10-04 EP EP10819948.0A patent/EP2484670B1/en active Active
- 2010-10-04 DK DK10819948.0T patent/DK2484670T3/en active
- 2010-10-04 AU AU2010302536A patent/AU2010302536B2/en active Active
- 2010-10-04 US US13/499,901 patent/US9604947B2/en not_active Expired - Fee Related

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
ES2360783A1 (en)	2011-06-09
AU2010302536A1 (en)	2012-05-31
WO2011039403A1 (en)	2011-04-07
ES2360783B1 (en)	2012-07-04
DK2484670T3 (en)	2016-10-24
EP2484670B1 (en)	2016-07-20
EP2484670A1 (en)	2012-08-08
AU2010302536B2 (en)	2016-09-15
CA2780695A1 (en)	2011-04-07
CA2780695C (en)	2019-08-20
US9604947B2 (en)	2017-03-28
US20120225879A1 (en)	2012-09-06

Publication	Publication Date	Title
EP2486060A4 (en)	2013-06-12	ANTI-SIGLEC ANTIBODIES IN THE TREATMENT OF DISEASES RELATED TO BONE LOSS
ATE434620T1 (en)	2009-07-15	DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP2684167A4 (en)	2014-10-15	COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
FR2948016B1 (en)	2012-05-18	ORTHESIS FOR THE TREATMENT OF RHIZARTHROSIS
HUE043171T2 (en)	2019-08-28	1-Arylcarbonyl-4-oxypiperidine Compounds useful in the treatment of neurodegenerative diseases
BR112012004546A2 (en)	2016-11-29	"dll4-ligand protein therapy"
BRPI0908026A2 (en)	2015-07-21	Methods for the treatment of bowel diseases
BRPI0814624A2 (en)	2015-01-27	TREATMENT OF PROGRESIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
EP2613795A4 (en)	2013-10-30	TREATMENT OF DISEASES
EP2613786A4 (en)	2013-10-23	TREATMENT OF DISEASES
BR112012002571A2 (en)	2016-11-29	titanium ore treatment
HUE054196T2 (en)	2021-08-30	Therapeutic agents for the treatment of diseases associated with unwanted cell proliferation
FR2934129B1 (en)	2014-05-02	COSMETIC TREATMENT PROCESS.
EP2623494A4 (en)	2014-04-02	AGENT FOR THE TREATMENT OF OCULAR DISEASES
EP2488507A4 (en)	2013-05-01	NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES
EP2493820A4 (en)	2013-09-25	WATER TREATMENT
BRPI0815551A2 (en)	2015-02-18	TREATMENT THROUGH HUCBC OF BETA-AMYLOID DISEASE
PL2726470T3 (en)	2015-09-30	1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
EP2967062A4 (en)	2016-10-19	DEETHYLHYDROXYCHLOROQUINE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION
IT1392551B1 (en)	2012-03-09	BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS
EP2484670A4 (en)	2013-03-13	SUBSTITUTED 1,2,4-TIADIAZOLES-5-IMINO USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP2387418A4 (en)	2013-07-17	TREATMENT OF PAIN
EP1835919A4 (en)	2010-01-20	TREATMENT AGAINST EYE DROUGHT
FR2934267B1 (en)	2010-08-13	AMINOPHOSPHINIC DERIVATIVES USEFUL IN THE TREATMENT OF PAIN
BRPI1010516A2 (en)	2015-08-25	Ischemia-reperfusion-related edema treatment methods

Legal Events

Date	Code	Title	Description
2012-07-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2012-08-08	17P	Request for examination filed	Effective date: 20120427
2012-08-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-01-09	DAX	Request for extension of the european patent (deleted)
2013-03-13	A4	Supplementary search report drawn up and despatched	Effective date: 20130213
2013-03-13	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 285/08 20060101AFI20130207BHEP Ipc: A61K 31/433 20060101ALI20130207BHEP
2014-04-16	17Q	First examination report despatched	Effective date: 20140313
2016-01-26	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2016-02-24	INTG	Intention to grant announced	Effective date: 20160127
2016-05-31	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2016-06-14	GRAR	Information related to intention to grant a patent recorded	Free format text: ORIGINAL CODE: EPIDOSNIGR71
2016-06-17	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2016-07-20	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-07-20	INTG	Intention to grant announced	Effective date: 20160614
2016-07-20	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2016-07-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2016-08-10	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2016-08-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 813969 Country of ref document: AT Kind code of ref document: T Effective date: 20160815
2016-08-25	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602010034938 Country of ref document: DE
2016-09-21	RIN2	Information on inventor provided after grant (corrected)	Inventor name: PALOMO RUIZ, VALLE Inventor name: LOZA GARCIA, MARIA ISABEL Inventor name: PEREZ CASTILLO, ANA MARIA Inventor name: PEREZ FERNANDEZ, DANIEL Inventor name: GIL AYUSO-GONTAN, CARMEN Inventor name: CADAVID TORRES, MARIA ISABEL Inventor name: MARTINEZ GIL, ANA Inventor name: BREA FLORIANI, JOSE Inventor name: PEREZ MARTIN, CONCEPCION
2016-10-05	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2016-10-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH
2016-10-24	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20161018
2016-10-25	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7
2016-11-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2016-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 813969 Country of ref document: AT Kind code of ref document: T Effective date: 20160720
2017-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161120 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161020
2017-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160720 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161021 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161121 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720
2017-04-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602010034938 Country of ref document: DE
2017-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720
2017-05-26	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2017-05-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2017-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161020 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720
2017-06-28	26N	No opposition filed	Effective date: 20170421
2017-07-26	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161004 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720
2017-10-13	REG	Reference to a national code	Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: RUE DU CENDRIER 15 CP 1489, 1201 GENEVE (CH)
2017-10-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8
2017-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161004
2018-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20101004
2018-06-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031
2018-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720
2024-11-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20241026 Year of fee payment: 15
2025-01-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20241029 Year of fee payment: 15
2025-01-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20241025 Year of fee payment: 15
2025-01-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FI Payment date: 20241025 Year of fee payment: 15
2025-01-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20241028 Year of fee payment: 15
2025-01-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20241025 Year of fee payment: 15
2025-01-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20241027 Year of fee payment: 15
2025-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20241101 Year of fee payment: 15